Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.

Tetsu Tomonari Yasushi SatoJoji TaniAkira HiroseChikara OgawaAkihiro MorishitaHironori TanakaTakahiro TanakaTatsuya TaniguchiKoichi OkamotoMasahiro SogabeHiroshi MiyamotoNaoki MugurumaKazushige UchidaTsutomu MasakiTetsuji Takayama

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)

Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
type diabetes
cancer therapy
patient reported outcomes
mesenchymal stem cells
bone marrow
skeletal muscle
replacement therapy
data analysis